Ambry Genetics

Join us for a webinar on Thursday, May 21, at 11 am PDT with Allison Wong, MS, CGC, and Setareh Zandihaghighi, MS, CGC. They will explore the efficacy of implementing multiple non-traditional service delivery models in community hospital-based cancer genetic clinics and the importance of equitable identification of those at increased risk for cancer. Register today: hubs.ly/Q04gznzB0 #genetictesting #GeneScene #CEUs #healthequity

What is the impact of concurrent DNA and RNA sequencing? +RNAinsight®, paired DNA/RNA testing, generates novel functional evidence that helps close data gaps and leads to a preferential improvement in accuracy among non-White populations. Dive deeper: hubs.ly/Q04gpnff0 #RNA #DNA #genetictesting #healthequity

While it is clear that de novo variants cause many rare genetic disorders, their detection currently requires full trio sequencing. Learn how duoNovo uses long-read sequencing to improve access to the most accurate testing for more patients by requiring only one biological parent. #genetictesting #raredisease  hubs.ly/Q04gcT_j0

In this Gene Scene, Jewel Wasson, MS, CGC, explores the SDHB gene and its association with SDHB-related Hereditary Pheochromocytoma-Paraganglioma and SDHB-related Mitochondrial Complex II Deficiency. #GeneScene #GeneChat #genetictesting hubs.ly/Q04gcLQk0

We’re proud to announce that the Ambry CARE Program® has been named Best Overall Health Informatics Solution in the 10th Annual MedTech Breakthrough Awards. Selected from more than 5,000 nominations worldwide, this recognition celebrates CARE’s global impact in digital health and medical technology. Read the press release: hubs.ly/Q04g58FK0

Today Ambry recognizes World Ovarian Cancer Day. Early detection saves lives. If you have a history of cancer in your family, talk to your healthcare provider about genetic testing to know your risks and help inform screening and treatment options. #WorldOvarianCancerDay #EarlyDetectionSavesLives #NoWomanLeftBehind

No clichés—just clarity. Ready to make high-risk workflows routine? Visit hubs.ly/Q04fClpD0.

Not all classification engines are created equal. As the genomic landscape becomes more complex, the tools we use to navigate it must do more than accurately interpret, they must evolve. 🌱 Our first-ever Annual Ambry Classifi® Impact Report is here, featuring a full year of data from 2025. Merging sophisticated algorithms with clinical expertise, Classifi keeps clinics at the forefront by powering lab-driven reanalysis through our Patient for Life™ program and driving global genomic equity for the betterment of all patients. Read the Report: hubs.ly/Q04fpyvR0

In this week's Gene Scene, Connolly Steigerwald, MS, CGC, explores the MYBP3 gene. Pathogenic variants in this gene have been associated with a spectrum of MYBPC3-related cardiomyopathies, including hypertrophic cardiomyopathy (HCM) and left ventricular noncompaction cardiomyopathy (LVNC). #GeneScene #GeneChat #Cardio hubs.ly/Q04fpzXn0

We are in Washington, DC, for #ACOG2026! Visit our booth to learn more about how OB-GYNs are uniquely positioned to help patients take proactive steps toward hereditary cancer detection and what it looks like to partner with Ambry. hubs.ly/Q04f5t6y0

This Patient Experience Week, Ambry recognizes our healthcare partners who work every day to provide more answers to more patients. Heather Fecteau highlights ways The Ambry CARE Program® (CARE) helps patients make better decisions by helping them understand their options. Education is built directly into the CARE experience, designed around how patients actually learn. Dive deeper: hubs.ly/Q04f5svl0 #CARE #genetictesting #hereditarycancer #empowered #informed

Join us for a webinar on Wednesday, May 6, at 10 am PDT/2 pm EDT. Scott Weissman, MS, CGC, will explore changes in direct-to-consumer testing and highlight practical strategies genetic counselors can use to support patients who pursue or bring results from this testing, while ensuring that consent remains meaningful and informed. #EducateNext #CEUs #GeneChat hubs.ly/Q04dCJ2q0

We are at in #ASBrS in Seattle. Meet with us to discuss how Ambry can support your practice by delivering fast, comprehensive genetic testing results to support personalized surgical decisions and offering digital technology options to identify at-risk patients and provide essential education. #genetictesting #BRCA #breastcancer #CARE hubs.ly/Q04f0NRz0

ICYMI: How can your clinic be a leader in the healthcare landscape of tomorrow? Dr. Kevin Banks demonstrates what is possible healthcare moves toward precision health and early detection Dive deeper: hubs.ly/Q04dJ5jF0 #CARE #hereditarycancer #genetictesting #breasthealth #precisionmedicine

Each week, we explore a gene from the ACMG Secondary Findings list. Join Brad Power, MS, CGC, and learn about the RYR1 gene and related pathogenic variants, including RYR1-related malignant hyperthermia susceptibility (MHS), and a spectrum of RYR1-related myopathies including central core disease (CCD), multi-minicore disease (MmD), dusty core disease (DuCD), centronuclear myopathy (CNM), and King-Denborough Syndrome (KDS). #GeneScene #GeneChat #genetictesting hubs.ly/Q04dB1-M0

Every April during Lab Week, we pause to celebrate the people whose work powers every test result, every insight, and every life changed through genetic testing. At Ambry Genetics, that celebration runs deep—because it truly takes a village. This year’s theme is especially fitting, because just like we focus on the patient behind every test, the Lab Story includes the lives of all the people who help with each sample. They truly go “to infinity and beyond for our patients.”

Representation matters. A lack of representation in clinical testing cohorts, published literature, and population reference data leads to reduced clinical utility due to limited evidence. For example, variants of uncertain significance (VUS) rates differ by REA group. How does Ambry fill in the gaps? MAVES (Multiplexed Assays of Variant Effect) Concurrent DNA and RNA sequencing Laboratory-initiated Reanalysis through Patient for Life™

Sarah Campian, MS, CGC, explores the TMEM127 gene and TMEM127-related hereditary pheochromocytoma-paraganglioma (PCC-PGL) in this Gene Scene covering a clinically actionable gene from the ACMG Secondary Findings List. #GeneScene #GeneChat hubs.ly/Q04cTwZ10

We are celebrating Medical Laboratory Professionals Week (April 19-25) at Ambry! This year’s theme, “Lab Story: To Infinity and Beyond for Our Patients,” truly embodies the spirit of our incredible team. We’re grateful for every lab worker whose dedication and innovation have helped Ambry achieve industry “firsts” and set new standards in personalized care. Every breakthrough and test performed is a testament to their commitment to excellence. Today and every day, we say thank you—your passion is making a real difference for patients and takes us all to infinity and beyond. #LabWeek #LaboratoryProfessionals #PatientCare #Innovation

Ambry is proud of its participation in access-focused efforts such as payer coverage expansion for exome and genome sequencing, patient assistance programs, improved reference resources, and proactive reanalysis. But access to genetic testing doesn’t necessarily mean equity for all patients. Equity also requires accuracy in interpretation across populations, which allows for confidence in clinical decision-making, or actionability. Ambry is driving more equitable accuracy in genetic testing by leveraging more diverse variant databases, rethinking validation strategies, and designing tools that increase actionability.